Eli Lilly and Company got a second emergency use authorization for a COVID-19 therapy on 19 November, this time for its rheumatoid arthritis drug Olumiant (baricitinib) as part of combination therapy with Gilead Sciences, Inc.’s Veklury (remdesivir) in hospitalized patients who require supplemental oxygen. Previously, its experimental neutralizing antibody bamlanivimab got EUA approval from the US Food and Drug Administration earlier this month to treat patients with mild-to-moderate COVID-19 symptoms.
Based on data from the National Institute for Allergy and Infectious Diseases ACTT-2 trial, the EUA covers treatment of patients...






